Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Neutral

Price to Earnings Rating

Buy

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

ReShape Lifesciences, Inc. Common Stock (RSLS)

Surgical & Medical Instruments & Apparatus

https://www.reshapelifesciences.com

Reshape Lifesciences Inc is a developer of minimally invasive medical devices to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus.

1001 CALLE AMANECER
SAN CLEMENTE, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

06/16/2021

Market Cap

5,380,760

Shares Outstanding

13,140,000

Weighted SO

18,520,978

Total Employees

N/A

Upcoming Earnings

08/05/2024

Similar Tickers

SINT --.--%

BBLG --.--%

RMED --.--%

TIVC --.--%

NUWE --.--%

TLIS --.--%

TNON --.--%

INVO --.--%

HSDT --.--%

Beta

1.3880

Last Div

0.0000

Range

0.141-1.29

Chg

0.0070

Avg Vol

6598338

Mkt Cap

5380760

Exch

NASDAQ

Country

US

Phone

949 429 6680

DCF Diff

3.3267

DCF

4.3372

Div Yield

0.0000

P/S

0.6687

EV Multiple

-0.4805

P/FV

1.5217

Div Yield %

0.0000

P/E

-0.5120

PEG

-0.0052

Payout

0.0000

Current Ratio

1.9016

Quick Ratio

0.8875

Cash Ratio

0.3602

DSO

62.6933

DIO

452.7283

Op Cycle

515.4216

DPO

143.6569

CCC

371.7647

Gross Margin

0.6747

Op Margin

-1.1511

Pretax Margin

-1.1132

Net Margin

-1.1211

Eff Tax Rate

-0.0070

ROA

-1.4109

ROE

-2.0837

ROCE

-2.9016

NI/EBT

1.0070

EBT/EBIT

0.9671

EBIT/Rev

-1.1511

Debt Ratio

0.0338

D/E

0.0712

LT Debt/Cap

0.0328

Total Debt/Cap

0.0664

Int Coverage

231.5500

CF/Debt

-40.1204

Equity Multi

2.1064

Rec Turnover

5.8220

Pay Turnover

2.5408

Inv Turnover

0.8062

FA Turnover

32.1840

Asset Turnover

1.2586

OCF/Share

-0.3436

FCF/Share

-0.3436

Cash/Share

0.0457

OCF/Sales

-1.0771

FCF/OCF

1.0000

CF Coverage

-40.1204

ST Coverage

-76.6903

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

1.5217

P/B

1.5217

P/S

0.6687

P/E

-0.5120

P/FCF

-0.6209

P/OCF

-0.5329

P/CF

-0.5329

PEG

-0.0052

P/S

0.6687

EV Multiple

-0.4805

P/FV

1.5217

DPS

0.0000

Latest Headlines (EST)

Benzinga May 02, 22:30 STOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The Merger - ALBT, NDOI, DNB, RSLS GlobeNewswire Inc. May 01, 23:00 $HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – ALBT, NDOI, DNB, RSLS GlobeNewswire Inc. Mar 23, 22:59 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates FNA, AVTE, RSLS on Behalf of Shareholders GlobeNewswire Inc. Feb 16, 04:17 ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering GlobeNewswire Inc. Dec 20, 08:31 ReShape Lifesciences® Engages Maxim Group LLC To Identify Strategic M&A Partnership Alternatives PennyStocks Dec 13, 17:30 3 Penny Stocks Under $1 To Watch After December Fed Meeting Benzinga Dec 12, 17:19 Why ReShape Lifesciences Jumped After-Hours GlobeNewswire Inc. Nov 06, 08:31 ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update

Revenue Product Segmentation